In the past few years, Drosophila has gained prominence as a tool for drug development due to its capacity to screen tiny compounds against intricate disease phenotypes in the setting of a complete animal. Gene-compound interaction studies combine compound feeding with complex genetic modifications in order to better investigate the compound mechanisms of response and resistance. These studies allow for a more in-depth exploration of the compound response and resistance mechanisms. In this section, I will discuss how the chemical screening and testing procedures performed on Drosophila may be applied to the process of generating novel cancer medicines in the present day. A framework for a Drosophila-based cancer drug discovery strategy is what I propose in order to assist the Drosophila research community in making the most of the benefits that Drosophila offers in terms of locating possible treatments and progressing our discoveries into the clinical setting.